[go: up one dir, main page]

CL2016000326A1 - Composiciones y método para tratar condiciones asociadas con el complemento - Google Patents

Composiciones y método para tratar condiciones asociadas con el complemento

Info

Publication number
CL2016000326A1
CL2016000326A1 CL2016000326A CL2016000326A CL2016000326A1 CL 2016000326 A1 CL2016000326 A1 CL 2016000326A1 CL 2016000326 A CL2016000326 A CL 2016000326A CL 2016000326 A CL2016000326 A CL 2016000326A CL 2016000326 A1 CL2016000326 A1 CL 2016000326A1
Authority
CL
Chile
Prior art keywords
complement
conditions associated
compositions
treat conditions
treat
Prior art date
Application number
CL2016000326A
Other languages
English (en)
Inventor
Brian Yaspan
Robert Royal Graham
Amy Dressen
Zhengrong Li
Erich Strauss
Teodorica Bugawan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2016000326A1 publication Critical patent/CL2016000326A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCIÓN PROPORCIONA COMPOSICIONES Y MÉTODO PARA TRATAR CONDICIONES ASOCIADAS CON EL COMPLEMENTO
CL2016000326A 2013-08-12 2016-02-11 Composiciones y método para tratar condiciones asociadas con el complemento CL2016000326A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361864941P 2013-08-12 2013-08-12
US201361866651P 2013-08-16 2013-08-16
US201361872098P 2013-08-30 2013-08-30
US201461988012P 2014-05-02 2014-05-02
US201462021487P 2014-07-07 2014-07-07

Publications (1)

Publication Number Publication Date
CL2016000326A1 true CL2016000326A1 (es) 2017-03-24

Family

ID=51422165

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000326A CL2016000326A1 (es) 2013-08-12 2016-02-11 Composiciones y método para tratar condiciones asociadas con el complemento

Country Status (18)

Country Link
US (3) US10093978B2 (es)
EP (1) EP3033436A1 (es)
JP (3) JP6463359B2 (es)
KR (2) KR20180021234A (es)
CN (1) CN107318267B (es)
AU (1) AU2014306867B2 (es)
BR (1) BR112016002845A2 (es)
CA (1) CA2920666A1 (es)
CL (1) CL2016000326A1 (es)
CR (1) CR20160132A (es)
EA (1) EA201690213A1 (es)
IL (1) IL243928A0 (es)
MX (1) MX2016001854A (es)
PE (1) PE20160192A1 (es)
PH (1) PH12016500302A1 (es)
SG (1) SG11201601044XA (es)
TW (1) TWI656217B (es)
WO (1) WO2015023596A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
AU2016344133A1 (en) * 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
CN106885910B (zh) * 2015-12-15 2018-12-21 上海吉涛生物科技有限公司 肿瘤易感微环境检测装置及试剂盒
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CN109706238B (zh) * 2017-10-26 2023-04-07 珠海岐微生物科技有限公司 一种老年性黄斑病变的检测与治疗方法
TWI831792B (zh) * 2018-06-12 2024-02-11 合一生技股份有限公司 靶向淋巴細胞活化基因3(lag-3)的核酸適體及其用途
CN109243567B (zh) * 2018-08-14 2021-11-02 山东科技大学 一种基于处方数据挖掘的药物推荐方法
CN109448781B (zh) * 2018-11-06 2021-09-14 云南大学 一种流感病毒抗原变化的预测方法
WO2020098630A1 (en) 2018-11-14 2020-05-22 Zhuhai Qiwei Bio-Technology Ltd. Animal models, screening methods, and treatment methods for intraocular diseases or disorders
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
CN114395620B (zh) * 2021-12-20 2022-09-20 温州谱希医学检验实验室有限公司 一种检测高度近视易感人群的生物标志物组合
CN117235479A (zh) * 2023-08-25 2023-12-15 上海金仕达软件科技股份有限公司 目标因子筛选方法及装置

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2703764B2 (ja) 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分Ｃ５ａに対するモノクローナル抗体
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5244800A (en) 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5981176A (en) 1992-06-17 1999-11-09 City Of Hope Method of detecting and discriminating between nucleic acid sequences
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
WO1994012219A2 (en) 1992-11-25 1994-06-09 Amgen Boulder Inc. Modified insulin-like growth factors
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
WO1994022466A1 (en) 1993-04-07 1994-10-13 Synergen, Inc. Methods of using insulin-like growth factor binding proteins
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
ES2236706T3 (es) 1994-03-23 2005-07-16 Alexion Pharmaceuticals, Inc. Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5919623A (en) * 1994-04-27 1999-07-06 St. James's And Seacroft University Hospitals Nhs Trust Nucleic acid mutation assays
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US5849483A (en) 1994-07-28 1998-12-15 Ig Laboratories, Inc. High throughput screening method for sequences or genetic alterations in nucleic acids
US5589330A (en) 1994-07-28 1996-12-31 Genzyme Corporation High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides
US5681736A (en) 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6239273B1 (en) 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3628333B2 (ja) 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6152681A (en) 1996-05-03 2000-11-28 Arrowhead Systems, Llc Container sweep for a palletizer and method
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
WO2001036432A2 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
EP0866071B1 (en) 1997-03-20 2004-10-20 F. Hoffmann-La Roche Ag Modified primers
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
SI1325932T1 (es) 1997-04-07 2005-08-31 Genentech Inc
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP1009861A4 (en) 1997-07-25 2002-10-16 Affymetrix Inc GENE EXPRESSION AND EVALUATION SYSTEM
US6223127B1 (en) 1997-08-15 2001-04-24 Affymetrix, Inc. Polymorphism detection utilizing clustering analysis
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
ES2270530T3 (es) 1997-08-26 2007-04-01 Amgen Fremont Inc. Un procedimiento para inhibir la activacion del completo por la via alternativa.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
CA2321140C (en) 1998-02-20 2015-04-07 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP2002523089A (ja) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド タンパク質輸送関連分子
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
WO2000036103A1 (en) 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE353339T1 (de) 1998-12-22 2007-02-15 Genentech Inc Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6136541A (en) 1999-02-22 2000-10-24 Vialogy Corporation Method and apparatus for analyzing hybridized biochip patterns using resonance interactions employing quantum expressor functions
EP1220905A2 (en) 1999-03-08 2002-07-10 Genentech Inc. Composition and methods for the treatment of immune related diseases
HU229376B1 (en) 1999-03-11 2013-11-28 Serono Lab Vascular adhesion molecules and modulation of their function
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001025485A2 (en) 1999-10-06 2001-04-12 Amersham Biosciences Corp Method for detecting mutations using arrayed primer extension
US6709816B1 (en) 1999-10-18 2004-03-23 Affymetrix, Inc. Identification of alleles
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001234962A1 (en) 2000-02-10 2001-08-20 Alexion Pharmaceuticals, Inc. Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
ES2316446T3 (es) 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
EE200300179A (et) 2000-10-13 2003-08-15 Biogen, Inc. Humaniseeritud LT-ß-R-i vastased antikehad
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
WO2004001009A2 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
WO2004041160A2 (en) 2002-10-30 2004-05-21 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US6864748B2 (en) 2003-01-31 2005-03-08 Lsi Logic Corporation Differential current amplifier with common mode rejection and high frequency boost
EP2422812A1 (en) 2003-02-21 2012-02-29 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP2267028A3 (en) 2003-06-30 2011-07-27 Domantis Limited Dual specific single domain antibodies (dAb) conjugated to PEG
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
BRPI0518289A2 (pt) 2004-11-18 2008-11-11 Univ Yale mÉtodos e composiÇÕes para o tratamento de desordens oculares
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP1833994A4 (en) 2005-01-04 2009-09-02 Hitachi Chemical Co Ltd ROLLING CIRCLE GAINING OF A PRIMER GENERATION
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP1907576B1 (en) 2005-06-08 2014-07-23 University of Pittsburgh of the Commonwealth System of Higher Education SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26
MX351152B (es) 2005-10-08 2017-10-04 Potentia Pharmaceuticals Inc Compstatina y analogos de la misma para tratar trastornos oculares.
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
KR20080104351A (ko) 2006-03-31 2008-12-02 노파르티스 아게 유기 화합물
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
JP2010504361A (ja) 2006-09-25 2010-02-12 メディミューン，エルエルシー 安定した抗体製剤およびその使用
JP2010508819A (ja) 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗ｄ因子抗体
KR20100014486A (ko) * 2007-04-30 2010-02-10 알콘 리서치, 리미티드 보체 인자 ｄ의 저해제를 사용한 연령 관련 황반변성의 치료
AU2008251801A1 (en) 2007-05-11 2008-11-20 The General Hospital Corporation Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
US20090203001A1 (en) * 2007-08-24 2009-08-13 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
EP2283163B1 (en) * 2008-04-18 2015-07-08 Tufts Medical Center Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
WO2009134709A2 (en) 2008-04-28 2009-11-05 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
RU2514658C2 (ru) 2008-06-25 2014-04-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Оптимизация растворимости иммуносвязывающих средств
ES2527653T3 (es) 2008-10-20 2015-01-28 F. Hoffmann-La Roche Ag Amplificación específica de alelo usando un cebador con un nucleótido modificado
CN101724144A (zh) 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
EP2540843B1 (en) * 2008-11-05 2014-07-02 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
WO2010075519A2 (en) 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Allelic variants associated with advanced age-related macular degeneration
BRPI0923810A2 (pt) 2009-01-02 2015-07-14 Alcon Res Ltd Implante oftálmico reabastecido no local
WO2010085542A2 (en) 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
WO2010132459A2 (en) * 2009-05-11 2010-11-18 Cleveland Clinic Foundation Biomarkers for assessment of age-related macular degeneration
CN107858381A (zh) 2009-07-02 2018-03-30 朗泽科技新西兰有限公司 醇生产方法
EP2451983B1 (en) * 2009-07-10 2015-05-06 The Regents of the University of Michigan Methods for diagnosing macular degeneration
US20120190578A1 (en) 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
WO2011061119A1 (en) 2009-11-19 2011-05-26 Merck Serono S.A. Humanized antibodies against human il-22ra
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
CN102108119A (zh) 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
MX348025B (es) 2010-11-01 2017-05-24 Genentech Inc * Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
WO2012082912A2 (en) * 2010-12-14 2012-06-21 Tufts Medical Center, Inc. Markers related to age-related macular degeneration and uses therefor
JP5942171B2 (ja) * 2011-03-30 2016-06-29 パナソニックＩｐマネジメント株式会社 車載用充電装置
ES2687951T3 (es) 2011-10-14 2018-10-30 F. Hoffmann-La Roche Ag Anticuerpos anti-HtrA1 y procedimientos de uso
JP6051998B2 (ja) 2012-03-30 2016-12-27 日油株式会社 マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
MX2016002720A (es) 2013-09-06 2016-06-08 Hoffmann La Roche Metodo para mejorar la estabilidad del anticuerpo.
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法

Also Published As

Publication number Publication date
JP2020028293A (ja) 2020-02-27
US20150044205A1 (en) 2015-02-12
JP6463359B2 (ja) 2019-01-30
JP2018064566A (ja) 2018-04-26
CN107318267B (zh) 2021-08-17
TW201512407A (zh) 2015-04-01
IL243928A0 (en) 2016-04-21
EP3033436A1 (en) 2016-06-22
CA2920666A1 (en) 2015-02-19
SG11201601044XA (en) 2016-03-30
WO2015023596A1 (en) 2015-02-19
JP2016537006A (ja) 2016-12-01
US10947591B2 (en) 2021-03-16
AU2014306867B2 (en) 2017-10-26
US10093978B2 (en) 2018-10-09
KR20180021234A (ko) 2018-02-28
US20190185935A1 (en) 2019-06-20
AU2014306867A1 (en) 2016-03-10
KR20160042438A (ko) 2016-04-19
PE20160192A1 (es) 2016-04-27
US20210207219A1 (en) 2021-07-08
TWI656217B (zh) 2019-04-11
EA201690213A1 (ru) 2016-07-29
CN107318267A (zh) 2017-11-03
CR20160132A (es) 2016-08-25
BR112016002845A2 (pt) 2017-09-12
MX2016001854A (es) 2016-09-06
PH12016500302A1 (en) 2016-05-02

Similar Documents

Publication Publication Date Title
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
IL259795A (en) Methods and compositions for treating a serpinc1-associated disorder
PL3206497T3 (pl) Kompozycje i sposoby leczenia zaburzeń czynności gruczołu Meiboma
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
UY37018A (es) Inhibidores bicíclicos de pad4
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
HUE051746T2 (hu) Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére
AP2017009674A0 (en) Methods and compositions for treating ulcers
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
PL3007695T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
UY36286A (es) Tratamientos médicos basados en anamorelina
PL3393468T3 (pl) Metody leczenia niedoboru odporności
MX2015003701A (es) Composiciones para tratamiento.
PL3280423T3 (pl) Kompozycje i sposoby do synergistycznego leczenia glikokaliksu
ZA201505875B (en) Compositions and methods for treating and repairing tendons
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi